Co-founder, CEO and President of Philogen. He graduated in Business Administration and Economics at the Bocconi University in Milan, specializing in Corporate Finance. Expertise in Financial Consulting, Tax and Audit Advisor and Business Administrator. Partner of the "Studio Neri - Tanini". Formerly in the Board of the University of Siena as a representative of the Italian Government, formerly auditor of the Cassa di Risparmio di San Miniato (CRSM) S.p.A., MPS Banca Verde S.p.A., MPS Fiduciaria S.p.A., MPS Professional S.p.A., and of several firms.
Co-founder and President of the Scientific Advisory Board of Philogen. He graduated in Chemistry at the Scuola Normale Superiore in Pisa and obtained his PhD in Chemistry from the ETH Zurich, under the supervision of Prof. Kurt Wüthrich, winner of the Nobel Prize for Chemistry, 2002. For his dissertation, he was awarded the Silver Medal of ETH. After a 5-year post-doctoral research position in the lab of Sir Gregory Winter at the Cambridge Centre of Protein Engineering in Cambridge, UK, he returned to the ETH Zurich in 1996 as Assistant Professor in Molecular Structure Biology. Since 1999, he has been a Professor in Biomacromolecules in the department of Chemistry and Applied Biosciences,(ETH).
He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe' Biotec Award 2000, of the Mangia d'Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer 2011 of the French Medicinal Chemistry Society and of the ERC Advanced Grant 2015.
Prof. Neri is author of more than 300 publications in international journals.
Co-founder and Director of IP & Licensing at Philogen S.p.A. Giovanni Neri graduated in Biology at the University of Siena where he also received his doctorate in Biotechnology. He later specialized in antibody therapeutics in clinical oncology at the Royal Postgraduate Medical School at the Hammersmith Hospital, London (1993-1995). As Director, he is responsible for developing the company's patent portfolio and is involved in the conclusion of all the major contractual agreements.
Sergio Dompé obtained three honorary degrees (pharmaceutical biotechnology from the University of Bologna in 1996, medical biotechnology from the University of L’Aquila in 2005 and pharmacy from the University of Urbino in 2010), as a result of his commitment to the pharmaceutical industry. In 1976, he started working for Dompé Farmaceutici S.p.A., founded by his father in 1940, and right from the start, brought many changes to the company’s strategy. He was among the first entrepreneurs in the industry to believe strongly in the opportunities offered by biotechnology for the development of new drugs. On the basis of this intuition, he established partnerships with global pharmaceutical companies to provide patients with new therapeutic benefits. Sergio Dompé holds the office of Chairman of Dompé Farmaceutici S.p.A., holding company of Dompé Group, which operates through three different companies, Dompé, Amgen Dompé and Biogen Dompé, and employs 800 persons globally and registered a turnover of 529.4 million Euros in 2010. From 1998 to 2004, Sergio Dompé was Chairman of Assobiotech for three consecutive terms in office. In June 2005 he was appointed President of Farmindustria, the Italian Pharmaceutical Companies’ Association and member of the Confindustria Council. Since January 2006, he has been Chairman of the Assessment Committee of the CNR (Italian Research Council). Since July 2007 he has been member of the Council of the Italian Institute of Technology foundation.
Nathalie Dompé is Vice President, Business Development at Dompé Pharmaceuticals and in charge of oversight, market development and strategic approval of all new programs launched by Dompé in the United States. Nathalie is concurrently CEO of Dompé Holdings, a diversified holding company in Europe with business interests in pharmaceuticals, agriculture and hi-tech. Nathalie is Board Director of several companies including Movendo, Bonifiche Ferraresi, Philogen and Dompé Pharmaceuticals. Born in Milan, Italy, in 1986, Nathalie graduated with Honors in Business Administration from Bocconi University in Milan.
Roberto Ferraresi graduated with honours in Business Administration at Bocconi University in Milan. Roberto started his career in 1998 in UBS Investment bank in London. He then joined PAI partners in 2004 where he became partner and was actively involved in deals where PAI partners invested more than €700 million and board member in both private and listed companies. Since January 2018 he is founder and CEO of The Equity Club , a private equity initiative in the form of club deal, promoted together with Mediobanca and counting more than 90 investors among the most prominent families in Italy.
Guido Guidi has 35 years’ experience from within the pharmaceutical industry. He was previously Head of Pharma Europe and Head of Oncology Europe at Novartis, where he was responsible for bringing various drugs from clinical development to market including Cosentryx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Sandostatin, Femara, Glivec and Jiakavi. While at Novartis, Guido originated and chaired the first edition of Bioupper, the Novartis accelerator for early-stage projects in Italy. He was also Chairman of the Novartis European Executive Committee and a member of the Innovation Management Board responsible for the Pharma division’s R&D program. He has also held different medical positions within Novartis, Sandoz, Roussel-UCLAF and GSK. Guido is currently Chairman, Co-Founder and Managing Partner of technology transfer company AurorA-TT.
Mr. Marsella currently serves as Head of Porftolio Strategy and Partnerships for Generali Real Estate, a large real estate investor with €30 billion of assets. Previously, he was Investment Director and Head of Business Development for Fondo Strategico Italiano/Cdp Equity, a large private equity investor in strategic Italian companies, and Chair of Investment and Risk Management Committee of the International Forum of Sovereign Wealth Funds (IFSWF). Mr Marsella has more than 30 years of experience in principal investments and advisory, both in the U.S and in Europe, having worked with small and large firms, including Merrill Lynch, UBS and Deutsche Bank. He has been serving on the board of directors of listed and private companies. His areas of expertise include: corporate finance, M&A, private equity and capital markets. His sectors of expertise include: energy, healthcare, technology and real estate. Mr. Marsella has a degree in Business Administration Summa cum Laude from Bocconi University in Milan and a Master in Business Administration, with major in Finance from the L. Stern School of Business of New York University.
Mr. Zambeletti is an Independent Strategic and Financial Advisor in the Healthcare sector. During a 20 year career as an investment banker, Mr Zambeletti led the EMEA Healthcare Investment Banking team at JP Morgan for eight years before taking up the same position at Credit Suisse for a further five years. He is a Non-Executive Director of Faron (AIM), Qardio Inc., Summit Therapeutics PLC (NASDAQ and AIM), Nogra Pharma, Okyo Pharma and Tiziana Life Sciences (AIM). Mr Zambeletti started his career at KPMG as an auditor and received a BA in Business from Bocconi University in Milan, Italy.